The Technical Analyst
Osmotica Pharmaceuticals [OSMT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Osmotica Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.77% $1.110
America/New_York / 19 jan 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 110.18 mill |
| EPS: | -1.599 |
| P/E: | -0.694 |
| Earnings Date: | Nov 15, 2021 |
| SharesOutstanding: | 99.26 mill |
| Avg Daily Volume: | 0.594 mill |
| RATING 2022-03-22 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.694 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.694 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.011 - 1.209 ( +/- 8.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-01-24 | Klein Christopher | Sell | 9 605 | Ordinary Shares |
| 2020-05-20 | Cowan Gregory L | Buy | 38 716 | Ordinary Shares |
| 2020-05-21 | Cowan Gregory L | Sell | 11 112 | Ordinary Shares |
| 2020-01-28 | Schaub James | Sell | 9 197 | Ordinary Shares |
| 2019-01-24 | Weiss Fred G | Buy | 34 403 | Ordinary Shares |
| INSIDER POWER |
|---|
| 0.00 |
| Last 6 transactions |
| Buy: 177 968 | Sell: 29 914 |
Forecast:
01:40 - $0.603
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.110 (-1.77% ) |
| Volume | 0.296 mill |
| Avg. Vol. | 0.594 mill |
| % of Avg. Vol | 49.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OSMT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OSMT
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2022-01-18 06:50:00 - Press Release
Rvl Pharmaceuticals To Host Upneeq® Overview And Business Update Webcast On January 19, 2022
-- topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- featured speakers include dr. jackie yee and dr. justin harper --
2021-12-20 16:05:00 - Press Release
Osmotica Pharmaceuticals Plc To Present At H.c. Wainwright Bioconnect Conference
Bridgewater, n.j., dec. 20, 2021 (globe newswire) -- osmotica pharmaceuticals plc (nasdaq: osmt) (“osmotica” or the “company”), a specialty pharmaceutical company, announced today that brian markison, chief executive officer, james “jd” schaub, chief operating officer, and andrew einhorn, chief financial officer, will present virtually at the h.c. wainwright bioconnect conference as follows:
2021-11-15 06:50:00 - Press Release
Osmotica Pharmaceuticals Plc To Present At Jefferies London Virtual Healthcare Conference 2021
Bridgewater, n.j., nov. 15, 2021 (globe newswire) -- osmotica pharmaceuticals plc (nasdaq: osmt) (“osmotica” or the “company”), a specialty pharmaceutical company, announced today that brian markison, chief executive officer, james “jd” schaub, chief operating officer, and andrew einhorn, chief financial officer, will present at the jefferies london virtual healthcare conference 2021 as follows:
2021-10-13 16:46:00 - Press Release
Osmotica Pharmaceuticals Plc Announces Closing Of $35 Million Underwritten Public Offering
Bridgewater, n.j., oct. 13, 2021 (globe newswire) -- osmotica pharmaceuticals plc (nasdaq: osmt) (“osmotica” or the “company”), a specialty pharmaceutical company, today announced that on october 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. the warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. the company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinary shares and/or warrants to purchase additional 2,100,000 ordinary shares at the public offering price, less the underwriting discounts and commissions...
2021-10-07 09:04:00 - Press Release
Osmotica Pharmaceuticals Plc Announces Debt Financing From Athyrium Capital Management Of Up To $100 Million
Bridgewater, n.j., oct. 07, 2021 (globe newswire) -- osmotica pharmaceuticals plc (nasdaq: osmt) (“osmotica” or the “company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by athyrium capital management (“athyrium”).
Latest News
2022-01-19 10:53:46 - Benzinga
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics.
2022-01-18 06:50:00 - GlobeNewsWire
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --
2021-12-20 16:05:00 - GlobeNewsWire
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
2021-11-15 21:01:02 - Seeking Alpha
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
2021-11-15 20:01:08 - Zacks Investment Research
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-15 06:50:00 - GlobeNewsWire
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows:
2021-10-13 16:46:00 - GlobeNewsWire
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinary shares and/or warrants to purchase additional 2,100,000 ordinary shares at the public offering price, less the underwriting discounts and commissions...
2021-10-09 11:33:40 - Pulse2
OSMT Stock: Why It Fell By Over 35% This Week
The stock price of Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) fell by over 35% this past week. This is why it happened.
2021-10-07 11:10:59 - Invezz
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to generate $35 million in gross proceeds from the offering Osmotica priced its previously announced public offering at $2.50 a share that represents an about […] The post Here's why Osmotica Pharmaceuticals is down 35% on Thursday appeared first on Invezz.
2021-10-07 09:04:00 - GlobeNewsWire
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management (“Athyrium”).